Roche to pay Blueprint up to $1.7 bln in cancer drug deal

This post was originally published on this site

By John Miller. ZURICH, July 14 (Reuters) – Swiss drugmaker Roche ROG.Son Tuesday struck a deal worth up to $1.7 billion with Blueprint Medicines BPMC.O to develop and commercialise a new treatment for people with so-called RET-altered cancers …

Click here to read full article